Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro

Figure 3

Antileukemic potential of atorvastatin (A) at 10 μM, cladribine + mafosfamide combination (CM), or atorvastatin in combination with cladribine + mafosfamide (CM + A) in comparison to the antileukemic potential of CM in PBMCs pretreated (or not) with atorvastatin at 1 μM.

(a)

(b)